Melanoma Tumor Mutational Burden and Indoor Tanning Exposure
JAMA Dermatology · 2025
DOI: 10.1001/jamadermatol.2024.4819 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Grace B Hanrahan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Melanoma Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Sunbathing, Ultraviolet Rays. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance UV-induced mutagenesis leads to a higher tumor mutational burden (TMB) in cutaneous melanoma relative to other cancer types. TMB is an important prognostic marker in advanced melanoma; higher TMB is associated with greater clinical response to immune checkpoint inhibition and improved survival.
Objective
To evaluate the association between cutaneous melanoma TMB and indoor tanning exposure, as well as other demographic, dermatologic, and tumor characteristics. Design, Setting, and Participants This retrospective cohort study took place at Dana-Farber Cancer Institute, a tertiary-care cancer treatment center in Boston, Massachusetts, between 2013 and 2022. Patients with a diagnosis of cutaneous melanoma for whom next-generation sequencing data and tanning bed exposure history were available were included. Exposures Indoor tanning exposure history, tumor characteristics, demographics, and dermatologic history were collected via retrospective medical record review. Main Outcomes and Measures The association of tanning bed use with TMB was modeled using inverse probability of treatment weighted, multivariable modeling.
Results
Among 617 patients (median [IQR] age at diagnosis, 61 [50-71] years; 337 [62.9%] male), there was no association between indoor tanning exposure and TMB after adjustment for demographic, tumor, and dermatologic characteristics (yes vs no: log 2 TMB [SE], 4.07 [0.44] vs 3.97 [0.45]; P = .39). However, there was a statistically significant association between higher TMB and older age at diagnosis, history of nonmelanoma skin cancer, and head and neck tumors relative to other primary sites. Average TMB was statistically significantly lower in patients with a history of abnormal nevi (yes vs no: log 2 TMB [SE], 3.89 [0.44] vs 4.15 [0.44]; P = .01). Conclusions and Relevance This cohort study suggests that indoor tanning exposure, while known to increase risk of melanoma, may not be meaningfully associated with melanoma TMB. Additional characteristics were associated with higher TMB and, thus, potentially improved immune checkpoint inhibitor response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Melanoma Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- University of Massachusetts T.H. Chan School of Medicine, Worcester.
- Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, Virginia.
- Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Hanrahan, G. B., Giobbie-Hurder, A., Allais, B., Vogelzang, J., Fay, C., & Tsibris, H. C. (2025). Melanoma Tumor Mutational Burden and Indoor Tanning Exposure. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.4819
Vancouver
Hanrahan GB, Giobbie-Hurder A, Allais B, Vogelzang J, Fay C, Tsibris HC. Melanoma Tumor Mutational Burden and Indoor Tanning Exposure. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.4819
BibTeX
@article{Hanrahan2025,
author = {Hanrahan, Grace B and Giobbie-Hurder, Anita and Allais, Blair and Vogelzang, Jayne and Fay, Christopher and Tsibris, Hillary C},
title = {Melanoma Tumor Mutational Burden and Indoor Tanning Exposure},
journal = {JAMA Dermatology},
year = {2025},
doi = {10.1001/jamadermatol.2024.4819}
}
EUVIMED